FBXO32通过调节NME1促进胃癌的进展
Xiong-Hui Rao1, Huaiyu Qiu1, Weifei Zhang1
1Department of Gastrointestinal Surgery, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, China.
Translational cancer research
|July 21, 2025
概括
F-box蛋白32 (FBXO32) 通过调节非转移性细胞1 (NME1) 来促进胃癌的进展. 针对FBXO32可能为预后不佳的胃癌患者提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 胃癌的发病率很高,存活率很低,尤其是转移性癌症.
- 确定新的治疗点对于改善患者的治疗结果至关重要.
- 在胃癌中F-box蛋白32 (FBXO32) 的作用在很大程度上仍未被描述.
研究的目的:
- 调查FBXO32在胃癌进展中的作用和潜在机制.
- 确定FBXO32表达和患者预后之间的关联.
- 探索FBXO32作为胃癌的潜在治疗点.
主要方法:
- 利用癌症基因组图集 (TCGA) 和基因表达总汇 (GEO) 数据库进行表达分析.
- 通过Western blot评估了FBXO32在细胞系中的表达.
- 通过各种体外和体内活体试验评估了扩散,迁移,入侵,茎状和瘤生长.
- 研究了FBXO32和非转移细胞1 (NME1) 之间的关系.
主要成果:
- 在胃癌组织和细胞系中,FBXO32的表达显著升高,与预后不佳相关.
- FBXO32敲击抑制了胃癌细胞的增殖,迁移,入侵和干细胞.
- FBXO32 knockdown 抑制了裸体小鼠的瘤形成,并增加了NME1的表达.
- NME1 knockdown部分扭转了FBXO32 knockdown对瘤的抑制作用.
结论:
- FBXO32促进胃癌的进展,可能通过调节NME1.1.
- FBXO32代表了胃癌的潜在治疗标.
- 研究结果提供了关于胃癌机制和潜在的新治疗策略的见解.
更多相关视频
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.7K
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
11.2K
相关概念视频
02:38Mitogens and the Cell Cycle
6.9K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.9K
02:07Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
02:26NF-κB-dependent Signaling Pathway
7.9K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.9K
02:17The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K